Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Company Limited, is located in Suzhou, Jiangsu Province.

愛(ài)美津制藥致力于仿制藥所涉及到全部階段的業(yè)務(wù)，是一家包括美國(guó)和中國(guó)多成員企業(yè)的集團(tuán)公司。集團(tuán)由愛(ài)美津制藥控股。美國(guó)市場(chǎng)的注冊(cè)和商業(yè)活動(dòng)由位于新澤西州，林赫斯特，美國(guó)愛(ài)美津負(fù)責(zé)；集團(tuán)的中國(guó)分公司，蘇州愛(ài)美津制藥有限公司，位于中國(guó)江蘇省蘇州市。

The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA.

愛(ài)美津制藥集團(tuán)目前在美國(guó)和中國(guó)均有藥品上市和銷售，同時(shí)我們擁有活躍的在研產(chǎn)品組，面向美國(guó)食品藥品監(jiān)督管理局（FDA）注冊(cè)和已申報(bào)若干個(gè)仿制藥品種（ANDA），并計(jì)劃開(kāi)展向中國(guó)食品藥品監(jiān)督管理局（CFDA）注冊(cè)和申報(bào)產(chǎn)品的工作。

Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

愛(ài)美津從事開(kāi)發(fā)的口服制劑產(chǎn)品，是開(kāi)發(fā)難度高，需要專門(mén)技術(shù)，或生產(chǎn)要求高度嚴(yán)格管理控制，以及法規(guī)復(fù)雜，需要規(guī)避或挑戰(zhàn)專利的仿制藥。愛(ài)美津集團(tuán)旗下公司或合作方開(kāi)發(fā)和生產(chǎn)的所有產(chǎn)品，都滿足高質(zhì)量標(biāo)準(zhǔn)，包括美國(guó)FDA。